Abstracts
Résumé
Vingt ans après la première description de l’antigène CD34, cette molécule continue de susciter la curiosité des scientifiques, qui cherchent toujours à élucider la fonction exacte de ce qui est rapidement apparu comme un « marqueur de la cellule souche hématopoïétique » dans différentes espèces incluant l’homme, les primates et la souris. Parallèlement, de nombreux outils ont été développés pour faire de CD34 un outil médical, essentiellement utilisé dans le diagnostic des hémopathies malignes et dans l’évaluation des greffons de cellules hématopoïétiques. Cet article présente les principales connaissances qui se sont accumulées au cours de vingt années d’études scientifiques et médicales.
Summary
Twenty years after the initial description of the CD34 antigen, scientists are still interested in elucidating the exact function of a prototypic « stem cell antigen » in human, primate and mouse models. While this question remains largely unresolved, this has not precluded the development of medical tools using the detection of CD34 in several applications that range from diagnosis of malignant blood diseases through the biological monitoring of haematopoietic cell collection for autologous or allogeneic transplantation. This review focuses on major aspects of CD34 biology.
Appendices
Références
- 1. Civin CL, Strauss LC, Brovall C, et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984 ; 133 : 157-65.
- 2. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997 ; 90 : 5002-12.
- 3. Salven P, Mustjoki S, Alitalo R, Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003 ; 101 : 168-72.
- 4. Baumhueter S, Dybdal N, Kyle C, Lasky LA. Global vascular expression of murine CD34, a sialomucin-like endothelial ligand for L-selectin. Blood 1994 ; 84 : 2554-65.
- 5. Tavian M, Coulombel L, Luton D, et al. Aorta-associated CD34+ hematopoietic cells in the early human embryo. Blood 1996 ; 87 : 67-72.
- 6. Trempus CS, Morris RJ, Bortner CD, et al. Enrichment for living murine keratinocytes from the hair follicle bulge with the cell surface marker CD34. J Invest Dermatol 2003 ; 120 : 501-11.
- 7. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal cells derived from adult bone marrow. Nature 2002 ; 418 : 41-9.
- 8. Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001 ; 105 : 369-77.
- 9. Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997 ; 3 : 1337-45.
- 10. Okuno Y, Iwasaki H, Huettner CS, et al. Differential regulation of the human and murine CD34 genes in hematopoietic stem cells. Proc Natl Acad Sci USA 2002 ; 99 : 6246-51.
- 11. Ito T, Tajima F, Ogawa M. Developmental changes of CD34 expression by murine hematopoietic stem cells. Exp Hematol 2000 ; 28 : 1269-73.
- 12. Okuno Y, Huettner CS, Radomska HS, et al. Distal elements are critical for human CD34 expression in vivo. Blood 2002 ; 100 : 4420-6.
- 13. Sassetti C, Van Zante A, Rosen SD. Identification of endoglycan, a member of the CD34/podocalyxin family of sialomucins. J Biol Chem 2000 ; 275 : 9001-10.
- 14. Felschow D, McVeigh ML, Hoehn GT. The adpater protein CrkL associates with CD34. Blood 2001 ; 97 : 3768-75.
- 15. Tada J, Omine M, Suda T, Yamaguchi N. A common signaling pathway via Syk and Lyn tyrosine kinases generated from capping of the sialomucins CD34 and CD43 in immature hematopoietic cells. Blood 1999 ; 93 : 3723-35.
- 16. Baumhueter S, Singer MS, Henzel W, et al. Binding of L-selectin to the vascular sialomucin CD34. Science 1993 ; 262 : 436-8.
- 17. Puri KD, Finger EB, Gaudernack G, Springer TA. Sialomucin CD34 is the major L-selectin ligand in human tonsil high endothelial venules. J Cell Biol 1995 ; 131 : 261-70.
- 18. Hiraoka N, Petryniak B, Nakayama J, et al. A novel, high endothelial venule-specific sulfotransferase expresses 6-sulfo sialyl Lewis(x), an L-selectin ligand displayed by CD34. Immunity 1999 ; 11 : 79-89.
- 19. van Zante A, Gauguet JM, Bistrup A, et al. Lymphocyte-HEV interactions in lymph nodes of a sulfotransferase-deficient mouse. J Exp Med 2003 ; 198 : 1289-300.
- 20. Traoré Y, Hirn J. Certain anti-CD34 monoclonal antibodies induce homotypic adhesion of leukemic cell lines in a CD18-dependent and a CD19-independent way. Eur J Immunol 1994 ; 24 : 2304-11.
- 21. Cheng J, Baumhueter S, Cacalano G, et al. Hematopoietic defects in mice lacking the sialomucin CD34. Blood 1996 ; 87 : 479-90.
- 22. Suzuki A, Andrew DP, Gonzalo JA, et al. CD34-deficient mice have reduced eosinophil accumulation after allergen exposure and show a novel crossreactive 90-kDa protein. Blood 1996 ; 87 : 3550-62.
- 23. Doyonnas R, Kershaw DB, Duhme C, et al. Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med 2001 ; 194 : 13-27.
- 24. Drew E, Merzaban JS, Seo W, et al. CD34 and CD43 inhibit mast cell adhesion and are required for optimal mast cell reconstitution. Immunity 2005 ; 22 : 43-57.
- 25. Andrews RG, Bryant AM, Bartelmez SH, et al. CD34+ marrow cells devoid of T and B lymphocytes reconstitute stable lymphopoiesis and myelopoiesis in lethally irradiated allogeneic baboons. Blood 1992 ; 80 : 1693-701.
- 26. Chabannon C, Cornetta K, Lotz JP, et al. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer : a randomized multicenter study. Br J Cancer 1998 ; 78 : 913-21.
- 27. Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma : results of a multicenter randomized controlled trial. J Clin Oncol 2001 ; 19 : 3771-9.
- 28. Urbano-Ispizua A, Rozman C, Pimentel P, et al. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. Blood 2001 ; 97 : 383-7.
- 29. Chabannon C. Le transfert incertain de la science vers la médecine : l’exemple des sytèmes de sélection de cellules CD34+. Med Sci (Paris) 1998 ; 14 : 183-7.
- 30. Reiffers J, Cailliot C, Dazey B, et al. Abrogation of post myeloablative chemotherapy neutropenia by ex vivo expanded autologous CD34 cells. Lancet 1999 ; 354 : 1092-3.
- 31. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001 ; 61 : 6451-8.
- 32. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combine immunodeficiency (SCID)-X1 disease. Science 2000 ; 288 : 669-72.
- 33. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995 ; 13 : 2547-55.
- 34. Migliaccio AR, Adamson JW, Stevens CE, et al. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation : graft progenitor cell content is a better predictor than nucleated cell quantity. Blood 2000 ; 96 : 2717-22.
- 35. Kanda Y, Hamaki T, Yamamoto R, et al. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia : an overview of 2483 patients from 22 studies. Cancer 2000 ; 88 : 2529-33.
- 36. Maynadie M, Gerland L, Aho S, et al. Clinical value of the quantitative expression of the three epitopes of CD34 in 300 cases of acute myeloid leukemia. Haematologica 2002 ; 87 : 795-803.